Testing a new lupus medicine given under the skin in children
Part of Immune system & allergy, Infections, Skin clinical trials.
This study tests anifrolumab, a new injection medicine that may help control systemic lupus erythematosus (SLE) in children and teens. Researchers will measure how the body processes the medicine and whether it helps reduce lupus activity while monitoring for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 5 to under 18 years old and weigh at least 15 kg (about 33 pounds)
- You have been diagnosed with systemic lupus erythematosus (SLE)
- Your SLE is currently moderate to severe (based on a specific disease activity score)
- You have been taking at least one standard lupus medicine for at least 4 weeks
- You have never received anifrolumab or certain other strong lupus medicines before
- You do not have serious kidney disease, brain/nervous system lupus, or recent herpes zoster infection from SLE
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an intravenous medicine called anifrolumab can safely improve active systemic lupus (SLE) in children. If you qualify, you may receive the study treatment and be closely monitored for safety and lupus symptoms.
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
This study tests an experimental drug called anifrolumab, which is given as an injection or infusion, to see how it works in people with active lupus. It may help reduce lupus symptoms by targeting the immune system.
This study tracks how well anifrolumab works and how safe it is for people with active lupus. It's a real-world look at the drug's effects, so no additional treatments or tests are required beyond what your doctor already prescribes.
This study looks at potential risks of the lupus medication anifrolumab in people with moderate to severe SLE. It focuses on serious infections and malignancies to see how safe the treatment is.
This study tests whether a medicine called anifrolumab can help reduce severe tiredness (fatigue) in people with lupus. It is for adults whose lupus is mostly under control but who still feel very tired.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.